CoChat

New precision medicine avenues to the prevention of Alzheimer’s disease from insights into the structure and function of γ-secretases

Open access
De Strooper, Bart, Karran, Eric · 2024 · The EMBO Journal

The DOI matches its Crossref record; the references it cites are not checked yet.

Abstract

Two phase-III clinical trials with anti-amyloid peptide antibodies have met their primary goal, i.e. slowing of Alzheimer’s disease (AD) progression. However, antibody therapy may not be the optimal therapeutic modality for AD prevention, as we will discuss in the context of the earlier small molecules described as “γ-secretase modulators” (GSM). We review here the structure, function, and pathobiology of γ-secretases, with a focus on how mutations in presenilin genes result in early-onset AD. Significant progress has been made in generating compounds that act in a manner opposite to pathogenic presenilin mutations: they stabilize the proteinase-substrate complex, thereby increasing the processivity of substrate cleavage and altering the size spectrum of Aβ peptides produced. We propose the term “γ-secretase allosteric stabilizers” (GSAS) to distinguish these compounds from the rather heterogenous class of GSM. The GSAS represent, in theory, a precision medicine approach to the prevention of amyloid deposition, as they specifically target a discrete aspect in a complex cell biological signalling mechanism that initiates the pathological processes leading to Alzheimer’s disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s44318-024-00057-w

Cites

Statistics

Figures

Figure 1 Processing of amyloid precursor protein to long and short amyloid peptides (Aβ). Amyloid precursor protein (APP) is a type I transmembrane protein, indicated at the top. The transmembrane domain (inserted in the membrane, blue) and the position of the β- and γ-secretase cleavage sites are indicated schematically. Beta-secretase is a type I transmembrane aspartyl-protease. We use in the text another name for β-secretase i.e., BACE1 (β-site amyloid precursor protein cleaving enzyme), because this name is preferred in the clinical trial literature. The β-secretase yields a soluble APPsβ that is secreted in the medium, and a membrane-bound APP carboxyterminal fragment that is 99 amino acid-long (APP-CTF99) and remains membrane bound. The primary amino acid sequence of APP-CTF99 is displayed and the precise positions of the β-secretase and the consecutive γ-secretase cleavage sites are indicated. The combined actions of β- and γ-secretases generate Aβ peptides of different lengths, as indicated by the black lines above and below the primary amino acid sequence. The γ-secretase complex (Fig. 2), which is also an aspartyl-protease, cleaves APP-CTF99 first close to the intracellular site of the cell membrane to generate Aβ49 and AICD50-99 (49-production line), or Aβ48 and AICD49-99 (48-production line). The AICD is released in the cytoplasm, while the Aβ48 and Aβ49 remain associated with the γ-secretase complex. The Aβ peptides are further trimmed by consecutive cleavages by γ-secretase removing tri- or tetrapeptides at each step (Takami et al, 2009). Alzheimer’s disease-causing mutations in the presenilin subunit of the γ-secretase complex destabilize the interaction with the Aβ peptides increasing the chance of premature release of incompletely digested Aβ species. This results in relative shifts of long versus short Aβ peptides, as explained in the text. Under physiological conditions, the most abundant peptide generated in this process is Aβ40, and clinical mutations increase the release of Aβ42 and/or Aβ43. However, currently, only Aβ37, Aβ38, Aβ40, Aβ42, and Aβ43 can be efficiently measured by ELISA, and the existence of other longer peptides in vivo remains to be proven. Evidence as discussed in the main text indicates, however, that the ratio of short (Aβ37 + Aβ38+Aβ40) over long (Aβ42 + Aβ43) correlates linearly (R2 = 0.78, p < 0.0001) with the age of onset of familial Alzheimer’s disease in presenilin mutation carriers (Petit et al, 2022a).
Figure 1 Processing of amyloid precursor protein to long and short amyloid peptides (Aβ). Amyloid precursor protein (APP) is a type I transmembrane protein, indicated at the top. The transmembrane domain (inserted in the membrane, blue) and the position of the β- and γ-secretase cleavage sites are indicated schematically. Beta-secretase is a type I transmembrane aspartyl-protease. We use in the text another name for β-secretase i.e., BACE1 (β-site amyloid precursor protein cleaving enzyme), because this name is preferred in the clinical trial literature. The β-secretase yields a soluble APPsβ that is secreted in the medium, and a membrane-bound APP carboxyterminal fragment that is 99 amino acid-long (APP-CTF99) and remains membrane bound. The primary amino acid sequence of APP-CTF99 is displayed and the precise positions of the β-secretase and the consecutive γ-secretase cleavage sites are indicated. The combined actions of β- and γ-secretases generate Aβ peptides of different lengths, as indicated by the black lines above and below the primary amino acid sequence. The γ-secretase complex (Fig. 2), which is also an aspartyl-protease, cleaves APP-CTF99 first close to the intracellular site of the cell membrane to generate Aβ49 and AICD50-99 (49-production line), or Aβ48 and AICD49-99 (48-production line). The AICD is released in the cytoplasm, while the Aβ48 and Aβ49 remain associated with the γ-secretase complex. The Aβ peptides are further trimmed by consecutive cleavages by γ-secretase removing tri- or tetrapeptides at each step (Takami et al, 2009). Alzheimer’s disease-causing mutations in the presenilin subunit of the γ-secretase complex destabilize the interaction with the Aβ peptides increasing the chance of premature release of incompletely digested Aβ species. This results in relative shifts of long versus short Aβ peptides, as explained in the text. Under physiological conditions, the most abundant peptide generated in this process is Aβ40, and clinical mutations increase the release of Aβ42 and/or Aβ43. However, currently, only Aβ37, Aβ38, Aβ40, Aβ42, and Aβ43 can be efficiently measured by ELISA, and the existence of other longer peptides in vivo remains to be proven. Evidence as discussed in the main text indicates, however, that the ratio of short (Aβ37 + Aβ38+Aβ40) over long (Aβ42 + Aβ43) correlates linearly (R2 = 0.78, p < 0.0001) with the age of onset of familial Alzheimer’s disease in presenilin mutation carriers (Petit et al, 2022a).CC BY · PubMed Central
Figure 2 Gamma-secretase complex embedded in the cell membrane. The four subunits are indicated in green (Nicastrin - NCT), red (Presenilin - PSEN), blue (Anterior pharynx defective - APH1), and orange (Presenilin enhancer - PSENEN). The structural coordinates can be found at 10.2210/pdb7D8X/pdb (Yang et al, 2021). Analysis of the data was done using the chimera package (v1. 17.3) (Pettersen et al, 2004).
Figure 2 Gamma-secretase complex embedded in the cell membrane. The four subunits are indicated in green (Nicastrin - NCT), red (Presenilin - PSEN), blue (Anterior pharynx defective - APH1), and orange (Presenilin enhancer - PSENEN). The structural coordinates can be found at 10.2210/pdb7D8X/pdb (Yang et al, 2021). Analysis of the data was done using the chimera package (v1. 17.3) (Pettersen et al, 2004).CC BY · PubMed Central
Figure 3 Binding sites of allosteric and orthosteric γ-secretase modulators and inhibitors. The ribbon structure of the γ-secretase complex is displayed and turned to show the binding sites of the allosteric modulator E2012 (red) and the inhibitors L625,458 (red), Semagacestat (yellow), and Avagacestat (magenta). The three inhibitors bind closely to each other at the catalytic site of the protease, while the modulator occupies the allosteric site in the complex. The structural coordinates can be found at 10.2210/pdbxxxx/pdb using PDB6LR4, 7D8X, and 6LGQ as pdb coordinates (Yang et al, 2021). Analysis of the data was done using the chimera package (v1. 17.3) (Pettersen et al, 2004).
Figure 3 Binding sites of allosteric and orthosteric γ-secretase modulators and inhibitors. The ribbon structure of the γ-secretase complex is displayed and turned to show the binding sites of the allosteric modulator E2012 (red) and the inhibitors L625,458 (red), Semagacestat (yellow), and Avagacestat (magenta). The three inhibitors bind closely to each other at the catalytic site of the protease, while the modulator occupies the allosteric site in the complex. The structural coordinates can be found at 10.2210/pdbxxxx/pdb using PDB6LR4, 7D8X, and 6LGQ as pdb coordinates (Yang et al, 2021). Analysis of the data was done using the chimera package (v1. 17.3) (Pettersen et al, 2004).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

The citation lists are queued

They are fetched later and appear here then.

References 161 · Cited by 36

Metadata

Authors
De Strooper, B., & Karran, E.
Affiliations
AbbVie (United States) (US)
Venue
The EMBO Journal
Published
2024-02-23
Volume
43
Issue
6
Pages
887-903
ISSN
  • 0261-4189 (ISSN-L)
  • 1460-2075
OpenAlex
W4392099111
Cited by
36
References
161
Citations by year
2026: 8 · 2025: 18 · 2024: 10
FWCI
2.05
Type
journal article
Language
en
Open access
Licence
Locations
  • The EMBO Journal (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • UCL Discovery (University College London) (submittedVersion, cc-by)
  • Lirias (submittedVersion, cc-by)
  • Figshare (submittedVersion, cc-by)
  • The Francis Crick Institute (cc-by)
Funders
  • EC | European Research Council (ERC-834682)
  • UK Research and Innovation (MR/Y014847/1)
  • Fonds Wetenschappelijk Onderzoek
  • Methusalem grant KULeuven
  • Queen Elisabeth Medical Foundation for Neurosciences
  • Belgian Alzheimer Research Foundation
  • The Alzheimer’s Association USA
  • Opening the Future
  • Bax-Van Luffelen foundation
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
Keywords
Alzheimer's disease, gamma-secretase, γ-secretase modulators, presenilin mutations, early-onset Alzheimer's disease, amyloid-beta, amyloid deposition, anti-amyloid antibodies, precision medicine, Alzheimer's disease prevention
MeSH terms
Alzheimer Disease, Humans, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Presenilins, Presenilin-1, Amyloid Precursor Protein Secretases, Precision Medicine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: New precision medicine avenues to the prevention of Alzheimer’s disease from insights into the structure and function of γ-secretases. https://app.cochat.ai/papers/10.1038/s44318-024-00057-w
The paper
De Strooper, B., & Karran, E. (2024). New precision medicine avenues to the prevention of Alzheimer’s disease from insights into the structure and function of γ-secretases. The EMBO Journal. https://doi.org/10.1038/s44318-024-00057-w

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.